Tenax Therapeutics Inc. (TENX) Director Gerald T. Proehl Purchases 29,882 Shares
Tenax Therapeutics Inc. (NASDAQ:TENX) Director Gerald T. Proehl purchased 29,882 shares of the stock in a transaction dated Wednesday, November 23rd. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $49,902.94. Following the transaction, the director now owns 15,433 shares of the company’s stock, valued at $25,773.11. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Tenax Therapeutics Inc. (NASDAQ:TENX) opened at 1.88 on Wednesday. The stock has a 50 day moving average of $1.68 and a 200 day moving average of $2.29. The company’s market cap is $52.86 million. Tenax Therapeutics Inc. has a 52-week low of $1.21 and a 52-week high of $3.40.
Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Thursday, November 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. On average, equities research analysts expect that Tenax Therapeutics Inc. will post ($0.65) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Tenax Therapeutics Inc. (TENX) Director Gerald T. Proehl Purchases 29,882 Shares” was originally published by Daily Political and is the propert of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/tenax-therapeutics-inc-tenx-director-gerald-t-proehl-purchases-29882-shares.html.
Tenax Therapeutics Company Profile
Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity.
Receive News & Ratings for Tenax Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.